Active substance
Lofexidine
- US FDA 4
- US price lines 2
- Safety 1
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| LUCEMYRA | EQ 0.18MG BASE | tablet · oral | BIOCORRX PHARMS | Prescription | 16 May 2018 |
| LOFEXIDINE HYDROCHLORIDE | EQ 0.18MG BASE | tablet · oral | REGCON HOLDINGS | Prescription | 20 Aug 2024 |
| LOFEXIDINE HYDROCHLORIDE | EQ 0.18MG BASE | tablet · oral | MSN | Prescription | 24 Feb 2025 |
| LOFEXIDINE HYDROCHLORIDE | EQ 0.18MG BASE | tablet · oral | NOVITIUM PHARMA | Prescription | 22 Oct 2025 |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | LOFEXIDINE 0.18 MG TABLET | $7.87932 | per EA | 23 Sep 2026 |
| US NADAC | LUCEMYRA 0.18 MG TABLET | $23.22082 | per EA | 19 Nov 2025 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Safety signals and safety-related labeling changes
- US FDA 5 Sep 2024 LUCEMYRA — safety-related labeling change
Labeling sections changed: Drug Interactions; Patient Counseling Information / Patient Information / Medication Guide
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.